Clinical Trial Update: A Study to Assess Change in Disease Activity and Adverse Events of Adalimumab in Chinese Participants Requiring High Dose Corticosteroids for Active Non-Infectious Intermediate, Posterior, or Pan-Uveitis [Phase 4]

View source ↗

Summary

Phase 4 study evaluating changes in disease activity and adverse events with adalimumab in Chinese participants with active non-infectious intermediate, posteri…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-infectious Intermediate Uveitis
• Non-infectious Pan-uveitis
• Non-infectious Posterior Uveitis

Drugs mentioned

• ADALIMUMAB (ADALIMUMAB-AATY)

Snippet

Sponsor: AbbVie | Conditions: Non-infectious Intermediate Posterior- or Pan-uveitis | Phase 4 | Status: COMPLETED